Department of Clinical Laboratory, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, China.
J Zhejiang Univ Sci B. 2024 May 17;25(6):471-484. doi: 10.1631/jzus.B2300029.
Infectious diseases are a great threat to human health. Rapid and accurate detection of pathogens is important in the diagnosis and treatment of infectious diseases. Metagenomics next-generation sequencing (mNGS) is an unbiased and comprehensive approach for detecting all RNA and DNA in a sample. With the development of sequencing and bioinformatics technologies, mNGS is moving from research to clinical application, which opens a new avenue for pathogen detection. Numerous studies have revealed good potential for the clinical application of mNGS in infectious diseases, especially in difficult-to-detect, rare, and novel pathogens. However, there are several hurdles in the clinical application of mNGS, such as: (1) lack of universal workflow validation and quality assurance; (2) insensitivity to high-host background and low-biomass samples; and (3) lack of standardized instructions for mass data analysis and report interpretation. Therefore, a complete understanding of this new technology will help promote the clinical application of mNGS to infectious diseases. This review briefly introduces the history of next-generation sequencing, mainstream sequencing platforms, and mNGS workflow, and discusses the clinical applications of mNGS to infectious diseases and its advantages and disadvantages.
传染病对人类健康构成巨大威胁。快速准确地检测病原体对于传染病的诊断和治疗至关重要。宏基因组下一代测序(mNGS)是一种用于检测样本中所有 RNA 和 DNA 的无偏和全面的方法。随着测序和生物信息学技术的发展,mNGS 正在从研究走向临床应用,为病原体检测开辟了新途径。大量研究表明,mNGS 在传染病中的临床应用具有很大的潜力,特别是在难以检测、罕见和新型病原体方面。然而,mNGS 的临床应用存在几个障碍,例如:(1)缺乏通用的工作流程验证和质量保证;(2)对高宿主背景和低生物量样本的不敏感;(3)缺乏大规模数据分析和报告解释的标准化指令。因此,全面了解这项新技术将有助于推动 mNGS 在传染病中的临床应用。本文简要介绍了下一代测序的历史、主流测序平台和 mNGS 工作流程,并讨论了 mNGS 在传染病中的临床应用及其优缺点。
J Zhejiang Univ Sci B. 2024-5-17
Crit Rev Microbiol. 2019-11-6
Microbiol Spectr. 2022-12-21
BMC Infect Dis. 2021-1-13
Zhongguo Dang Dai Er Ke Za Zhi. 2022-2-15
Annu Rev Pathol. 2018-10-24
Front Med (Lausanne). 2025-8-11
Indian J Crit Care Med. 2025-6
Front Cell Infect Microbiol. 2025-4-15
Am J Ophthalmol. 2022-10
EBioMedicine. 2021-12
Nat Biotechnol. 2021-11
Front Cell Infect Microbiol. 2021
Front Cell Infect Microbiol. 2021